Pharmacogenetics of asthma: Toward precision medicine

Current Opinion in Pulmonary Medicine

Volumn 23, Issue 1, 2017, Pages 12-20

  Kersten, Elin T G ^a,b   Koppelman, Gerard H ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b GRIAC Research Center   (Netherlands)

Author keywords

Asthma; Pharmacogenetics; Precision medicine

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ASTHMA; CORTICOSTEROID THERAPY; GENETIC ASSOCIATION; HUMAN; META ANALYSIS (TOPIC); PERSONALIZED MEDICINE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; PROCEDURES;

ASTHMA; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; PHARMACOGENETICS; PRECISION MEDICINE;

EID: 84992065224     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000335     Document Type: Review

References (54)

1. Chung KF. Asthma phenotyping: A necessity for improved therapeutic precision and new targeted therapies. J Intern Med 2016; 279: 192-204.
2. Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: A roadmap to asthma control. Eur Respir J 2015; 46: 622-639.
3. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372: 793-795.
4. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-1512.
5. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): A genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374: 1754-1764.
6. Wechsler ME, Yawn BP, Fuhlbrigge AL, et al. Anticholinergic vs long-acting beta-agonist in combination with inhaled corticosteroids in black adults with asthma: The BELT randomized clinical trial. JAMA 2015; 314: 1720-1730.
7. Basu K, Palmer CN, Tavendale R, et al. Adrenergic beta (2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J All Clin Immunol 2009; 124: 1188-1194.
8. Turner S, Francis B, Vijverberg S, et al. Childhood asthma exacerbations and the Arg16 beta2-receptor polymorphism: A meta-analysis stratified by treatment. J All Clin Immunol 2016; 138: 107-113.
9. Lipworth BJ, Basu K, Donald HP, et al. Tailored second-line therapy in asthmatic children with the Arg (16) genotype. Clin Sci (Lond) 2013; 124: 521-528.
10. Himes BE, Jiang X, Hu R, et al. Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene. PLoS Genet 2012; 8: E1002824.
11. Padhukasahasram B, Yang JJ, Levin AM, et al. Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups. Pharmacogenomics J 2014; 14: 365-371.
12. Israel E, Lasky-Su J, Markezich A, et al. Genome-wide association study of short-acting beta2-agonists. A novel genome-wide significant locus on chromosome 2 near ASB3. Am J Respir Crit Care Med 2015; 191: 530-537.
13. Blake K, Lima J. Pharmacogenomics of long-acting b2-agonists. Expert Opin Drug Metab Toxicol 2015; 11: 1733-1751.
14. Tantisira KG, Small KM, Litonjua AA, et al. Molecular properties and pharmacogenetics of a polymorphismof adenylyl cyclase type 9 in asthma: Interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet 2005; 14: 1671-1677.
15. Poon AH, Tantisira KG, Litonjua AA, et al. Association of corticotropinreleasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. Pharmacogenet Genomics 2008; 18: 373-382.
16. Litonjua AA, Lasky-Su J, Schneiter K, et al. ARG1 is a novel bronchodilator response gene: Screening and replication in four asthma cohorts. Am J Respir Crit Care Med 2008; 178: 688-694.
17. Vonk JM, Postma DS, Maarsingh H, et al. Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response. Pharmacogenet Genomics 2010; 20: 179-186.
18. Duan QL, Gaume BR, Hawkins GA, et al. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med 2011; 183: 449-454.
19. Duan QL, Du R, Lasky-Su J, et al. A polymorphism in the thyroid hormone receptor gene is associated with bronchodilator response in asthmatics. Pharmacogenomics J 2013; 13: 130-136.
20. Drake KA, Torgerson DG, Gignoux CR, et al. A genome-wide association study of bronchodilator response in Latinos implicates rare variants. J Allergy Clin Immunol 2014; 133: 370-378.
21. Duan QL, Lasky-Su J, Himes BE, et al. A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics J 2014; 14: 41-47.
22. Ortega VE, Hawkins GA, Moore WC, et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting beta agonist treatment in a multiethnic asthma population: A genetic study. Lancet Resp Med 2014; 2: 204-213.
23. Kim SH, Ye YM, Lee HY, et al. Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy. J Clin Pharm Ther 2011; 36: 399-405.
24. Iordanidou M, Paraskakis E, Tavridou A, et al. G894T polymorphism of eNOS gene is a predictor of response to combination of inhaled corticosteroids with long-lasting beta2-agonists in asthmatic children. Pharmacogenomics 2012; 13: 1363-1372.
25. Hawkins GA, Lazarus R, Smith RS, et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J Allergy Clin Immunol 2009; 123: 1376-1383.
26. Vijverberg SJ, Koster ES, Tavendale R, et al. ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults. Clin Exp Allergy 2015; 45: 1051-1059.
27. Keskin O, Uluca U, Birben E, et al. Genetic associations of the response to inhaled corticosteroids in children during an asthma exacerbation. Pediatr Allergy Immunol 2016; 27: 507-513.
28. Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011; 365: 1173-1183.
29. Hosking L, Bleecker E, Ghosh S, et al. GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma. J Allergy Clin Immunol 2014; 133: 587-589.
30. Vijverberg SJ, Tavendale R, Leusink M, et al. Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. Pharmacogenomics 2014; 15: 799-806.
31. Dahlin A, Denny J, Roden DM, et al. CMTR1 is associated with increased asthma exacerbations in patients taking inhaled corticosteroids. Immun Inflamm Dis 2015; 3: 350-359.
32. Wang Y, Tong C, Wang Z, et al. Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma. Pharmacogenomics J 2015; 15: 422-429.
33. Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13: 1353-1359.
34. Berce V, Kozmus CE, Potocnik U. Association among ORMDL3 gene expression, 17q21 polymorphism and response to treatment with inhaled corticosteroids in children with asthma. Pharmacogenomics J 2013; 13: 523-529.
35. Leusink M, Vijverberg SJ, Koenderman L, et al. Genetic variation in uncontrolled childhood asthma despite ICS treatment. Pharmacogenomics J 2016; 16: 158-163.
36. Tantisira KG, Hwang ES, Raby BA, et al. TBX21: A functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A 2004; 101: 18099-18104.
37. Tantisira KG, Silverman ES, Mariani TJ, et al. FCER2: A pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol 2007; 120: 1285-1291.
38. Koster ES, Maitland-van der Zee AH, Tavendale R, et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroidtreated asthmatic children. Allergy 2011; 66: 1546-1552.
39. Kim MH, Kim SH, Kim YK, et al. A polymorphism in the histone deacetylase 1 gene is associated with the response to corticosteroids in asthmatics. Korean J Intern Med 2013; 28: 708-714.
40. Stockmann C, Fassl B, Gaedigk R, et al. Fluticasone propionate pharmacogenetics: CYP3A4-22 polymorphism and pediatric asthma control. J Pediatr 2013; 162: 1222-1227.
41. Tantisira KG, Damask A, Szefler SJ, et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med 2012; 185: 1286-1291.
42. Park HW, Dahlin A, Tse S, et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J Allergy Clin Immunol 2014; 133: 664-669.
43. Chang HS, Heo JS, Shin SW, et al. Association between TAAR6 polymorphisms and airway responsiveness to inhaled corticosteroids in asthmatic patients. Pharmacogenet Genomics 2015; 25: 334-342.
44. Perin P, Potocnik U. Polymorphisms in recent GWA identified asthma genes CA10, SGK493, and CTNNA3 are associated with disease severity and treatment response in childhood asthma. Immunogenetics 2014; 66: 143-151.
45. Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to antiasthma treatment. Nat Genet 1999; 22: 168-170.
46. Asano K, Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A (444)C polymorphism and clinical response to a CYS-LT (1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12: 565-570.
47. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173: 379-385.
48. Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17: 189-196.
49. Tantisira KG, Lima J, Sylvia J, et al. 5-lipoxygenase pharmacogenetics in asthma: Overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics 2009; 19: 244-247.
50. Dahlin A, Litonjua A, Irvin CG, et al. Genome-wide association study of leukotriene modifier response in asthma. Pharmacogenomics J 2016; 16: 151-157.
51. Dahlin A, Litonjua A, Lima JJ, et al. Genome-wide association study identifies novel pharmacogenomic loci for therapeutic response to montelukast in asthma. PLoS One 2015; 10: E0129385.
52. Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol 2012; 130: 516-522.
53. Nakamura Y, Suzuki R, Mizuno T, et al. Therapeutic implication of genetic variants of IL13 and STAT4 in airway remodelling with bronchial asthma. Clin Exp Allergy 2016; 46: 1152-1161.
54. Wu AC, Gay C, Rett MD, et al. Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving. Pharmacogenomics 2015; 16: 591-600.